Clinical responses to EGFR-tyrosine kinase inhibitor retreatment in non-small cell lung cancer patients who benefited from prior effective gefitinib therapy: a retrospective analysis

BACKGROUND: Gefitinib was the first epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) approved for the treatment of advanced non-small cell lung cancer (NSCLC). Few treatment options are available for NSCLC patients who have responded to gefitinib treatment and demonstrated tumor...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Hoofdauteurs: Watanabe, Satoshi, Tanaka, Junta, Ota, Takeshi, Kondo, Rie, Tanaka, Hiroshi, Kagamu, Hiroshi, Ichikawa, Kosuke, Koshio, Jun, Baba, Junko, Miyabayashi, Takao, Narita, Ichiei, Yoshizawa, Hirohisa
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: BioMed Central 2011
Onderwerpen:
Research Article
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC3022883/
https://ncbi.nlm.nih.gov/pubmed/21194487
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1471-2407-11-1
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items